微小残留病
多发性骨髓瘤
残余物
医学
内科学
重症监护医学
计算机科学
算法
骨髓
出处
期刊:PubMed Central
[National Institutes of Health]
日期:2024-12-14
卷期号:45 (12): 1065-1070
被引量:1
标识
DOI:10.3760/cma.j.cn121090-20241111-00444
摘要
The application of standardized criteria to evaluate treatment efficacy is crucial for guiding therapeutic decisions, assessing prognosis, and interpreting outcomes in treating multiple myeloma (MM). The unique characteristics of MM make its response assessment more complex compared with other malignancies. It primarily depends on serum and urine M protein levels, combined with the number of plasma cells in the bone marrow and comprehensive imaging findings. Recently, the emergence of novel therapeutics has led to significant improvements in MM outcomes. Minimal residual disease (MRD) detection determines deeper remission states. The clinical significance of MRD monitoring is now widely recognized. The Chinese Society of Clinical Oncology (CSCO) MM Expert Committee and the Hematologic Oncology Committee of the Chinese Anti-Cancer Association (CACA) have gathered relevant experts to develop the guidelines based on these advancements, aiming to provide a comprehensive reference for response assessment in MM.
科研通智能强力驱动
Strongly Powered by AbleSci AI